Quince therapeutics completes the sale of legacy protease inhibitor portfolio to lighthouse pharmaceuticals

South san francisco, calif.--( business wire )--quince therapeutics, inc. (nasdaq: qncx), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, announced the sale of the company's legacy small molecule protease inhibitor portfolio, including cor588, cor388, cor852, and cor803, pursuant to an asset purchase agreement with lighthouse pharmaceuticals, inc., an entity co-founded by casey lynch, former chief executive officer of quince's predecessor company cortexyme.
QNCX Ratings Summary
QNCX Quant Ranking